Advertisement
Canada markets open in 2 hours 59 minutes

  • S&P/TSX

    22,259.47
    +312.06 (+1.42%)
     

  • S&P 500

    5,180.74
    +52.95 (+1.03%)
     

  • DOW

    38,852.27
    +176.59 (+0.46%)
     

  • CAD/USD

    0.7309
    -0.0012 (-0.16%)
     

  • CRUDE OIL

    78.35
    -0.13 (-0.17%)
     

  • Bitcoin CAD

    87,337.41
    -1,364.16 (-1.54%)
     

  • CMC Crypto 200

    1,325.18
    -39.94 (-2.92%)
     

  • GOLD FUTURES

    2,322.50
    -8.70 (-0.37%)
     

  • RUSSELL 2000

    2,060.67
    +24.95 (+1.23%)
     

  • 10-Yr Bond

    4.4890
    -0.0110 (-0.24%)
     

  • NASDAQ futures

    18,171.25
    -24.25 (-0.13%)
     

  • VOLATILITY

    13.56
    +0.07 (+0.52%)
     

  • FTSE

    8,302.37
    +88.88 (+1.08%)
     

  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     

  • CAD/EUR

    0.6789
    -0.0003 (-0.04%)
     

Valeant CEO 'disappointed' in Allergan poison pill: CNBC

Reuters
A sample of Botox is seen at the Long Island Plastic Surgical Group at the Americana Manhasset luxury shopping destination in Manhasset, New York September 30, 2010. REUTERS/Shannon Stapleton (Reuters)

(Reuters) - The chief executive officer of Valeant Pharmaceuticals, which made a $47 billion unsolicited offer for competitor Allergan Inc on Tuesday, said during an interview on CNBC that he was "disappointed" with Allergan's so-called poison pill. Allergan on Tuesday night said its board of directors had adopted a one-year stockholder rights plan to give it more time to consider takeover proposals. The Valeant offer was made with Pershing Square Capital Management hedge fund, which built up a stake in the company. "We are disappointed but on the other hand, I think this deal will get done," Valeant CEO Michael Pearson said on Wednesday. (Reporting by Caroline Humer; Editing by Chizu Nomiyama)